{"name":"Entos Pharmaceuticals","slug":"entos","ticker":"Private","exchange":"Private","domain":"entospharma.com","description":"Entos Pharmaceuticals is a private company focused on gene therapy and drug delivery. The company is developing innovative treatments for various diseases. Entos has a strong pipeline of products, including several promising candidates in clinical trials. As a private company, Entos does not publicly disclose its financial information, but it has received significant funding from investors.","hq":"Edmonton, Canada","founded":0,"employees":"","ceo":"John Lewis","sector":"Gene Therapy / Drug Delivery","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"Private","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"ETX101 patent cliff ($500M at risk)","drug":"ETX101","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"COVIGENIX VAX- 002","genericName":"COVIGENIX VAX- 002","slug":"covigenix-vax-002","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"COVIGENIX VAX- 002","genericName":"COVIGENIX VAX- 002","slug":"covigenix-vax-002","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-15","type":"deal","headline":"Entos Pharmaceuticals Raises $100M in Series C Funding","summary":"Entos Pharmaceuticals announced that it has raised $100 million in Series C funding to support the development of its gene therapy and drug delivery technologies.","drugName":"","sentiment":"positive"},{"date":"2023-09-01","type":"trial","headline":"Entos Pharmaceuticals Initiates Phase 2 Clinical Trial for Gene Therapy Candidate","summary":"Entos Pharmaceuticals announced that it has initiated a Phase 2 clinical trial for its gene therapy candidate, which is being developed for the treatment of a rare genetic disorder.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNZFk0RG1VcUNiYzEwSmJnUURoajZOc2NqcHZhYjVYXzB3QnJIOEZEQXhhM2U5U1dQWXhxekNkdDJaU2NmRXZFZkttbVoyUGs4aDNkQmxUSzd3T3Jkb2xvUFAyQjJLU3pVbzRJeGNvdXhQMkRCa3dhdHlabmZMVkg1dDRCZm4zaXNBTEZ1OVp4YnJINHlmN3Eta2V3?oc=5","date":"2025-12-02","type":"pipeline","source":"BioSpace","summary":"Pharma 4.0 Market Size Worth USD 81.20 Billion By 2034 - BioSpace","headline":"Pharma 4.0 Market Size Worth USD 81.20 Billion By 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQNVBqWVR5dGljb3N6MUtwVk8yN2d5SlZIMmlLSEROdjllTHdnd00tVkJ2LWFuVVJjZnhmOWNMb2h5ajN0cTJlVHlWU2VSTzdfS0FveWhHRjZkVkFJZkxuWVE2ajJsd1BGSENWODZRNDVWWjgzNl9zOEMzWUotOVJCbU5nQXdqNmk1MHF0RUdoakRjZzFYNkhuUURfdF9nNGE2dXNHMVl0ZWJXT0NZd0UwNkRpaDE3ZVZ6MHpqZ2hRaFA1MlE?oc=5","date":"2025-07-18","type":"pipeline","source":"Fierce Pharma","summary":"Bain Capital, Botanic move ahead with MA manufacturing facility designed to serve multiple biotechs - Fierce Pharma","headline":"Bain Capital, Botanic move ahead with MA manufacturing facility designed to serve multiple biotechs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxQR1Bnend6ZVJVSF9PaWYtRy1BMUp3UVVaNTh3UkFPTTZMTHN6bEZfNk5odjE4N2FFMmxHVWRSbEZ0cU9ldUU3YmhmQW1ZNm9tOWZTZVJST1lNMFgyWmVfWF95c3ZjWnBhS2RsZ2FiSm4xbkp1QWdvTDBRQ25QV0hzR1JmUkVqZE5XOWNCTUctY2lCd2ItNmVHMHdEcnQ2cVp5OGZkeGMzYzdtTGdDSElSZXdTVXdZVEh6TVJmUTQxUG5QNjB0cE5YSVhxcFowLTNwV2JxVF9MaXRFejJzOTRoZGpiVU5LZFpyS3FCMmZIdkR1a01yOWtyUU1UeWZtSnBfYmZrQmpHcm0?oc=5","date":"2025-05-22","type":"pipeline","source":"PR Newswire","summary":"CureDuchenne Ventures Invests in Entos Pharmaceuticals for Development of a Redosable, Full-Length Dystrophin Gene Therapy - PR Newswire","headline":"CureDuchenne Ventures Invests in Entos Pharmaceuticals for Development of a Redosable, Full-Length Dystrophin Gene Thera","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxONkdIZXpBcHJhNjFmVGV4MUthWmRSRzZSZ213WXNIalRhYk9yVVNaN0lrSzlOYjNGM3lRSklIekZjbC1IZGhNTy11dkgtSTdWWVRZaU0xVW1FSG1mcVBLT3ZlS2xyX2F5YmtMYlNJNmRZZ29Pdzd5RnRlTm5ZVzlRSk4xUTdheVU4WTRtSUJ5RkxhQ0tvWlhtNFhhLURUcjFCUjBBS1JUZENuMndDNzA1SlFuRFFxeUxrNFd3S3BwQkE3cDZj?oc=5","date":"2022-01-06","type":"deal","source":"Eli Lilly","summary":"Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications - Eli Lilly","headline":"Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxPSFpUa0MzZF9URmhBQWZZTzRPVkVaQzFTaUl3X2gtYWpqNU56RWlzOHNENkwtSkpaOV9YbU5od1dmbHdxN3ZuQ1ZqdUVOMTltVkpBaUlrSTFJZXVkdWdKUko4XzdvNVBYeTUwMFNuUTZoRnhybE9aNXdLUFdvNG9fc1ZVZGNLR1pHNnVqd0JhOWp3NjJMMXJ5R1VKS1c1bVA2R2dCZUtnUDc4VmIyam5qWkdEeGx4LVF3anNsWlVRQmF1MmNMOXY1S1JTMmJMXzV2R1lud0YzQUhvVUhmRTZzaUIxZFVDb0lhb0lqWWd3?oc=5","date":"2021-12-01","type":"pipeline","source":"University of Alberta","summary":"New provincial research funding for U of A aims to create made-in-Alberta vaccine and drug development pipeline - University of Alberta","headline":"New provincial research funding for U of A aims to create made-in-Alberta vaccine and drug development pipeline","sentiment":"neutral"}],"patents":[{"drugName":"ETX101","drugSlug":"etx101","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":500000000}],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Spark Therapeutics","uniQure","Voyager Therapeutics"],"therapeuticFocus":["Gene Therapy","Drug Delivery"],"financials":null,"yahoo":null}